直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

PTAB v. District Court: When a Claim is Indefinite Lacks Reasonable Certainty

May 13, 2016

Authored and Edited by Anthony A. Hartmann; James D. Stein

In a Petition for Inter Partes Review, a petitioner may challenge patent claims as being anticipated and/or obvious. 35 U.S.C. §311(b). A challenge based on 35 U.S.C. §112, such as indefiniteness, is unavailable. However, indefiniteness may become an issue during claim construction, particularly for means-plus-function limitations.

In nearly a dozen cases, the PTAB has denied institution because it found that the petitioner did not show a limitation to be definite. In certain of those cases, the PTAB has concluded that “Petitioner has not demonstrated that the recitation of [a limitation]... viewed in light of the specification and prosecution history, sufficiently informs those skilled in the art about the scope of the invention with reasonable certainty,” and thus “has not shown a reasonable likelihood that it would prevail.” Medshape, Inc. v. Cayenne Medical, Inc., IPR2015-00848 (Sept. 14, 2015) (Paper 9) at 11-12. In Medshape, the PTAB applied the Supreme Court’s opinion in Nautilus, Inc. v. Biosig Instruments, Inc., 134 S.Ct. 2120, 2124 (2014), that a claim is indefinite if it fails to inform, with reasonable certainty, about the scope of the invention. Id. at 8.

While Medshape failed to institute a recent IPR against certain claims, it was recently able to obtain a summary judgment ruling of invalidity in a parallel district court proceeding. Cayenne Medical, Inc. v. Medshape, Inc., No. 2.14-cv-0451, slip op. at 15 (D. Ariz. May 6, 2016). In particular, the district court found the PTAB’s finding of indefiniteness to be compelling evidence of invalidity in that particular case. Id. at 8. This appears to be the first district court finding of indefiniteness based on a PTAB decision.

This contrasts with Fortinet v. Sophos, where the district court reached the opposite conclusion under similar facts. Based on the PTAB’s denial of institution for indefiniteness in Fortinet, Inc. v. Sophos, Inc., IPR2015-00617 (August 13, 2015) (Paper 9) at 18-19, Fortinet sought summary judgment of invalidity before the district court. Fortinet, Inc. v. Sophos, Inc., 2015 U.S. Dist. LEXIS 146317, at *13 (N.D. Cal. Oct. 28, 2015). There, the Court found a lack of clear and convincing evidence that the claims were indefinite. Id. at *25-26. While the Court found the PTAB decision “persuasive” in some aspects, it emphasized that the decision was “not binding in any way,” and that “the PTAB was not asked to invalidate based on indefiniteness.” Id. at *28 & n.4.

The differences in outcome may reflect several variables regarding these decisions. First, a PTAB decision is not binding on a district court. Second, the PTAB found the petitioner to have failed to establish the term to be definite; not that Petitioner established indefiniteness. Third, different panels may reach different conclusions on the issue of a claim’s definiteness. Compare IPR2014-01170 (no institution) with IPR2015-01872 (institution). Finally, the PTAB decisions were only one factor considered by either Court.

Tags

indefiniteness (35 USC § 112)

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Contacts

Anthony A. Hartmann
Of Counsel
Washington, DC
+1 202 408 4275
Email

Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

2026 Copyright Society Annual Meeting

June 14-16, 2026

Louisville

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

Reception

12th Annual Georgia Asian Pacific American Bar Association Gala

May 21, 2026

Atlanta

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP